Oral Acute exacerbations of chronic bronchitis, Acute respiratory disorders associated with excessive mucus production, Chronic respiratory disorders associated with excessive mucus production
Adult: As cap or dispersible tab: 300 mg bid or tid. Treatment duration for acute exacerbations of chronic bronchitis not to exceed 10 days. As susp: 350 mg bid. Dosing recommendations may vary among individual products or preparations and between countries (refer to specific product guidelines). Child: As susp: 15-<20 kg: 175 mg bid; 20-30 kg: 175 mg tid; >30 kg: Same as adult dose. Dosing recommendations may vary among individual products or preparations and between countries (refer to specific product guidelines).
What are the brands available for Erdosteine in Indonesia?
Mild to moderate: Max: 300 mg daily. Severe: Contraindicated.
Administration
cap: May be taken with or without food.
Reconstitution
Powder for oral susp: Reconstitute with the appropriate volume of water, shake well.
Contraindications
Active peptic ulcer. Severe renal (CrCl <25 mL/min) and hepatic impairment (including hepatic cirrhosis and cystathionine-synthase deficiency). Children (<2 years).
Special Precautions
Mild to moderate hepatic impairment. Children. Pregnancy and lactation.
Symptoms: Dizziness, sweating, flushing. Management: Symptomatic and supportive treatment. May perform gastric lavage if necessary.
Action
Description: Mechanism of Action: Erdosteine is a prodrug which becomes active after metabolism whereby free thiol groups are formed. This results in the opening of disulfide bonds in bronchial mucoproteins thus reducing mucous viscosity. Additionally, it inhibits bacterial adhesion to epithelial cells. Pharmacokinetics: Absorption: Rapidly absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 1 hour. Distribution: Plasma protein binding: 50-86%. Metabolism: Undergoes rapid first-pass metabolism to N-thiodiglycolyl-homocysteine (active metabolite). Excretion: Via urine (as active metabolite and sulfates). Elimination half-life: 1.46 hours (erdosteine); 1.62 hours (N-thiodiglycolyl-homocysteine).
Chemical Structure
Erdosteine Source: National Center for Biotechnology Information. PubChem Database. Erdosteine, CID=65632, https://pubchem.ncbi.nlm.nih.gov/compound/Erdosteine (accessed on Jan. 22, 2020)
Sign Out
